LONDON & MELBOURNE, Australia–(BUSINESS WIRE)–Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical corporate specialising in neuroscience drug discovery and early scientific building, is happy to announce the a success crowning glory of its Section 1 Section A comparative trial comparing the security and pharmacokinetics of its leading edge cast dose prescription cannabidiol (CBD), SAP021.
The sure result of this Section 1 Section An ordeal reveal the tolerability and bioavailability of Sapient Therapeutics lead asset, SAP021, compared to Epidiolex®. The trial met all pharmacokinetic necessities, marking a vital milestone within the building of SAP021. In consequence, the Corporate has stepped forward this cast dose CBD candidate into Section B of the trial with complete effects anticipated in H1 2024.
Giles Moss, Leader Government Officer of Sapient Therapeutics commented: “A cast dose method of CBD may provide further scientific receive advantages to sufferers experiencing and affected by severe neurological sicknesses. Those preliminary effects verify the early doable of SAP021, are in line with our best-case situation at this level and set us up neatly for continuation of this trial to a a success result”.
Sapient Therapeutics plans to utilise an U.S. Meals and Drug Management (FDA) expedited and de-risked 505(b)(2) regulatory pathway, with a purpose to creating a cast dose CBD prescription medication commercially to be had for US sufferers in overdue H2 2027.
For and on behalf of Sapient Therapeutics Ltd:
Sapient Therapeutics is a UK based totally biopharmaceutical corporate excited about neuroscience drug discovery and early scientific building. Our lead asset (SAP021) has commenced Section 1 research and can whole in 2024. Our management workforce is constituted of neuroscience and cannabinoid medication veterans. In combination we’re utilising the revel in won in cannabinoid drug building to deliver new prescription drugs to sufferers affected by severe sicknesses.
STx PR001 Nov2023
Giles Moss, CEO